Rabbit Anti-Human RBP4 (a.a. 18-201) Polyclonal antibody

Name: Rabbit Anti-Human RBP4 (a.a. 18-201) Polyclonal antibody
SKU: DPABH-17487
Rating: 5 (1 reviews)

Rabbit Anti-Human RBP4 (a.a. 18-201) Polyclonal antibody for ELISA, IHC, WB

Write a review

COA

SDS

Datasheet

Key features and details

Target: Human RBP4
Host: Rabbit
Application: ELISA, IHC, WB
Species Reactivity: Human, Mouse, Rat

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human; Mouse; Rat

Immunogen

E. coli - derived recombinant Human RBP4 (Ala18-Leu201).

Conjugate

Unconjugated

Applications

Application Notes

ELISA: 1:4000-1:8000
IHC: 1:50-1:100
WB: 1:1000-1:4000

General Notes

This product (Catalog No. DPABH-17487) is a rabbit-derived polyclonal antibody raised against human RBP4, targeting the amino acid region 18–201 of the protein. This antibody exhibits cross-reactivity with Human RBP4 from mouse and rat. It has been affinity purified by Protein A. Retinol-binding protein 4 (RBP4), also known as serum retinol-binding protein, is a 21 kDa monomeric protein belonging to the lipocalin superfamily that functions as the primary transport carrier for retinol (vitamin A) in human plasma. It circulates predominantly as a complex with transthyretin (TTR) to prevent renal filtration and glomerular loss, enabling the solubilization and delivery of the hydrophobic retinol molecule from hepatic stores to peripheral tissues via receptor-mediated mechanisms, such as the stimulated by retinoic acid 6 (STRA6) receptor. Structurally, RBP4 features a characteristic eight-stranded β-barrel fold that forms a hydrophobic cavity for high-affinity retinol binding (Kd ≈ 10 nM), with an N-terminal coil, C-terminal α-helix, and three disulfide bridges stabilizing the 183-amino-acid mature polypeptide. Crystal structures reveal additional capacity to bind fatty acids like oleic and linoleic acid in the same pocket, hinting at potential roles beyond retinoid transport.
DPABH-17487 is suitable for use in ELISA (1:4,000–1:8,000), IHC (1:50–1:100), Western blot (WB) (1:1,000–1:4,000) applications.
DPABH-17487 is supplied as a liquid formulation in 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.

Target

Alternative Names

PRBP; Plasma retinol-binding protein; RBP4; Retinol-binding protein 4; RBP

UniProt ID

P02753

Citations

Have you cited DPABH-17487 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Components of Boiogito Suppress the Progression of Hypercholesterolemia and Fatty Liver Induced by High-Cholesterol Diet in Rats

YONAGO ACTA MEDICA

Authors: Qian, Weibin; Hasegawa, Junichi; Cai, Xinrui; Yang, Jie; Ishihara, Yoshitaka; Ping, Bingqiong; Tsuno, Satoshi; Endo, Yusuke; Matsuda, Akiko; Miura, Norimasa

Abstract

Background Ogi, one main component of boiogito (BOT), is reported to have an effect on hypercholesterolemia and NAFLD. In this experiment, we examined effects of ogi on the progression of hypercholesterolemia and fatty liver induced by high-cholesterol diet in rats and compared with the effects of ogi combined with ginger or hesperidin. Methods Hypercholesterolemia and fatty liver were induced by a high cholesterol diet in rats. Extract of ogi, ogi with hesperidin, and ogi with ginger were added to the high-cholesterol diet, respectively. Ezetimibe was also added to the high-cholesterol diet as a positive control. After 6 and 12 weeks, body, liver and adipose tissue weights, blood chemistry, lipid-related and inflammatory-related factors were examined. Result The high cholesterol diet increased body, liver and adipose tissue weights, and serum cholesterol concentrations. Ogi, ogi with hesperidin or ginger and ezetimibe improved them. In the histological examinations, we observed a significant improvement after treatment. The lipid-related factors (RBP4, HFABP and CFABP) were improved by treatment. Biomarkers of cholesterol synthesis (lathosterol) and absorption (campesterol, betasitosterol) were lower in the treatment groups. Inflammatory-related factors (MCP1, CCR2 and TNF-alpha) and ICAM-1 were ameliorated after treatment, especially by ogi with ginger. Conclusion Ogi, ogi with hesperidin or ginger have a similar effect of BOT and ezetimibe on hypercholesterolemia and fatty liver. Ogi with ginger reveals a stronger additive effect with no significant difference. However, as for the anti-inflammatory (MCP1, CCR2 and TNF-alpha) and anti-arteriosclerotic (ICAM-1) effects, additive effects of ogi with ginger are more potent than that of ogi alone or ezetimibe.

Proteomics Analysis for Finding Serum Markers of Ovarian Cancer

BIOMED RESEARCH INTERNATIONAL

Authors: Cheng, Yushan; Liu, Chongdong; Zhang, Nawei; Wang, Shengdian; Zhang, Zhenyu

Abstract

A combination of peptide ligand library beads (PLLB) and 1D gel liquid chromatography-mass spectrometry/mass spectrometry (1DGel-LC-MS/MS) was employed to analyze serum samples from patients with ovarian cancer and from healthy controls. Proteomic analysis identified 1200 serum proteins, among which 57 proteins were upregulated and 10 were downregulated in the sera from cancer patients. Retinol binding protein 4 (RBP4) is highly upregulated in the ovarian cancer serum samples. ELISA was employed to measure plasma concentrations of RBP4 in 80 samples from ovarian cancer patients, healthy individuals, myoma patients, and patients with benign ovarian tumor, respectively. The plasma concentrations of RBP4 ranging from 76.91 to 120.08 ng/mL with the mean value 89.13 +/- 1.67 ng/mL in ovarian cancer patients are significantly higher than those in healthy individuals (10.85 +/- 2.38 ng/mL). Results were further confirmed with immunohistochemistry, demonstrating that RBP4 expression levels in normal ovarian tissue were lower than those in ovarian cancer tissues. Our results suggested that RBP4 is a potential biomarker for diagnostic of screening ovarian cancer.